+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Global Castleman Disease Treatment Market by Disease Type (Multicentric Castleman's Disease, Unicentric Castleman's Disease), Indication (Angiofollicular Lymph Node Hyperplasia, Angiomatous Lymphoid, Castleman Tumor), Treatment, Application - Forecast 2024-2030

  • PDF Icon

    Report

  • 191 Pages
  • June 2024
  • Region: Global
  • 360iResearch™
  • ID: 5336683
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Castleman Disease Treatment Market grew from USD 294.33 million in 2023 to USD 334.15 million in 2024. It is expected to continue growing at a CAGR of 13.62%, reaching USD 719.87 million by 2030.

Recent years have observed an increased prevalence of rare diseases, including Castleman disease, necessitating enhanced treatment options. The understanding of Castleman disease has advanced over the years, leading to the development of targeted therapies. Ongoing research focuses on identifying biomarkers, understanding the underlying pathophysiology, and discovering novel treatment options. Some treatments for Castleman disease have received orphan drug designation, which provides incentives for pharmaceutical companies to develop therapies for rare diseases. However, the high cost of drug development, limited treatment options, and strict regulatory compliance impede the expansion of treatment. Healthcare professionals, researchers, and advocacy groups are collaborating on a global scale to improve the diagnosis, management, and treatment of Castleman disease.

Regional Insights

The Americas, particularly the U.S. and Canada, has a relatively well-established infrastructure for rare disease diagnosis and treatment, including Castleman disease. There are specialized medical centers and experts focused on the condition, and patient advocacy groups and research institutes have contributed to the awareness and advancements in diagnosis and treatment. In Asia, access to castle treatment is limited when compared to the other regions; however, the government investment in healthcare development has significantly strived toward a more focused approach to rare diseases. Major cities in the region offer advanced diagnostic and treatment options, and small-scale academic institutes in China, Japan, and India are investing heavily in R&D activities. In Europe, the government promotes stakeholder cooperation in healthcare and research activities, benefiting the treatment of Castleman disease. The European Medicines Agency has been working on reviewing improved medications and approving them to elevate the provision and access to Castleman treatment to patients in the region.

Market Insights

Market Dynamics

  • The market dynamics represent an ever-changing landscape of the Castleman Disease Treatment Market by providing actionable insights into factors, including supply and demand levels. Accounting for these factors helps design strategies, make investments, and formulate developments to capitalize on future opportunities. In addition, these factors assist in avoiding potential pitfalls related to political, geographical, technical, social, and economic conditions, highlighting consumer behaviors and influencing manufacturing costs and purchasing decisions.

Market Drivers

  • Prevalence of Castleman disease and the need for effective disease management
  • Provision of orphan drug designation and approvals for Castleman disease treatments
  • Rise of patient advocacy groups and awareness programs for Castleman treatment

Market Restraints

  • Complexities in the drug development for Castleman disease

Market Opportunities

  • Ongoing advancements in the development of new Castleman disease treatment
  • Emerging trend of personalized medicine for Castleman disease treatment

Market Challenges

  • Lack fo standardized treatment protocols

Market Segmentation Analysis

  • Disease type: Need for rapid deployment of treatment strategies for multicentric Castleman’s disease due to the chances of systemic organ failure
  • Indication: Rising adoption of Castlemann’s disease treatment options for tackling angiomatous lymphoid cases
  • Treatment: Advancements in chemotherapy treatments leading to expanding adoption of Castleman disease treatment options
  • Application: Preference for ambulatory surgical centers due to provision of optimum patient care

Industry Insights

  • Market Disruption Analysis
  • Porter’s Five Forces Analysis
  • Value Chain & Critical Path Analysis
  • Pricing Analysis
  • Technology Analysis
  • Patent Analysis
  • Trade Analysis
  • Regulatory Framework Analysis

FPNV Positioning Matrix

The FPNV positioning matrix is essential in evaluating the market positioning of the vendors in the Castleman Disease Treatment Market. This matrix offers a comprehensive assessment of vendors, examining critical metrics related to business strategy and product satisfaction. This in-depth assessment empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success, namely Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The market share analysis is a comprehensive tool that provides an insightful and in-depth assessment of the current state of vendors in the Castleman Disease Treatment Market. By meticulously comparing and analyzing vendor contributions, companies are offered a greater understanding of their performance and the challenges they face when competing for market share. These contributions include overall revenue, customer base, and other vital metrics. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With these illustrative details, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Recent Developments

FDA Approves Tocilizumab Biosimilar Tofidence

The US Food and Drug Administration (FDA) approved Tofidence (tocilizumab-bavi) as the first biosimilar to Actemra (tocilizumab). Tofidence was developed through a partnership between Biogen and Bio-Thera Solutions. Tocilizumab is a monoclonal antibody that targets IL-6R, an immunosuppressant drug used for treating rheumatoid arthritis and systemic juvenile idiopathic arthritis in children. It is also approved for Castleman's disease, a rare benign tumor of B cells, in Japan. This approval signifies an important advancement in the treatment options available for Castleman's disease.

Chugai Obtains Approval for Additional Indication of Actemra for Cytokine Release Syndrome Induced by Cancer Therapy in Japan

Chugai Pharmaceutical Co., Ltd. received approval from the Japanese Ministry of Health, Labour and Welfare for an additional indication of treatment of Castleman Disease with their humanized anti-human IL-6 receptor monoclonal antibody, Actemra Intravenous Infusion. This expands the original indication for treating cytokine release syndrome induced by tumor-specific T-cell infusion therapy to incorporate other cancer treatments.

Medable Partners with Every Cure to Accelerate Discovery of Treatments for Rare Diseases

Medable Inc., a technology platform for patient-centered clinical trials, partnered with Every Cure, a non-profit organization established in collaboration with the Clinton Global Initiative. The objective of this partnership is to identify potential treatments for rare conditions, including Castleman disease.

Strategy Analysis & Recommendation

The strategic analysis is essential for organizations seeking a solid foothold in the global marketplace. Companies are better positioned to make informed decisions that align with their long-term aspirations by thoroughly evaluating their current standing in the Castleman Disease Treatment Market. This critical assessment involves a thorough analysis of the organization’s resources, capabilities, and overall performance to identify its core strengths and areas for improvement.

Key Company Profiles

The report delves into recent significant developments in the Castleman Disease Treatment Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Agilent Technologies, Inc., Amgen Inc., Artiva Biotherapeutics, Inc., Bayer AG, Bio-Rad Laboratories, Inc., Biogen Inc., Boehringer Ingelheim GmbH, Bristol-Myers Squibb Company, Cadila Pharmaceuticals Limited, Celltrion Healthcare Co.,Ltd., F. Hoffmann-La Roche AG, Gilead Sciences, Inc., GlaxoSmithKline PLC, Glenmark Pharmaceuticals S.A., Johnson & Johnson Services, Inc., LGM Pharma, Merck & Co., Inc., Novartis AG, Octapharma AG, Pfizer, Inc., Recordati Group Company, Recordati S.p.A., Sanofi S.A., Sartorius AG, Sun Pharmaceutical Industries Ltd., Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., Thermo Fisher Scientific Inc., and Viatris Inc..

Market Segmentation & Coverage

This research report categorizes the Castleman Disease Treatment Market to forecast the revenues and analyze trends in each of the following sub-markets:

Disease Type

  • Multicentric Castleman’s Disease
  • Unicentric Castleman’s Disease

Indication

  • Angiofollicular Lymph Node Hyperplasia
  • Angiomatous Lymphoid
  • Castleman Tumor
  • Giant Benign Lymphoma
  • Giant Lymph Node Hyperplasia
  • Hamartoma of the Lyphatics

Treatment

  • Antiviral Drugs
  • Chemotherapy
  • Corticosteroids
  • Immunotherapy
  • Monoclonal Antibodies
  • Radiation Therapy

Application

  • Ambulatory Surgical Centers
  • Hospitals

Region

Americas

  • Argentina
  • Brazil
  • Canada
  • Mexico
  • United States
  • California
  • Florida
  • Illinois
  • New York
  • Ohio
  • Pennsylvania
  • Texas

Asia-Pacific

  • Australia
  • China
  • India
  • Indonesia
  • Japan
  • Malaysia
  • Philippines
  • Singapore
  • South Korea
  • Taiwan
  • Thailand
  • Vietnam

Europe, Middle East & Africa

  • Denmark
  • Egypt
  • Finland
  • France
  • Germany
  • Israel
  • Italy
  • Netherlands
  • Nigeria
  • Norway
  • Poland
  • Qatar
  • Russia
  • Saudi Arabia
  • South Africa
  • Spain
  • Sweden
  • Switzerland
  • Turkey
  • United Arab Emirates
  • United Kingdom

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website

Please note: For this report, the purchase of an Enterprise license allows up to ten worldwide users of an organization access to the report

Purchase of this report includes 1 year online access with quarterly updates

Purchase of this report includes 1 year online access with quarterly updates

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Prevalence of Castleman disease and the need for effective disease management
5.1.1.2. Provision of orphan drug designation and approvals for Castleman disease treatments
5.1.1.3. Rise of patient advocacy groups and awareness programs for Castleman treatment
5.1.2. Restraints
5.1.2.1. Complexities in the drug development for Castleman disease
5.1.3. Opportunities
5.1.3.1. Ongoing advancements in the development of new Castleman disease treatment
5.1.3.2. Emerging trend of personalized medicine for Castleman disease treatment
5.1.4. Challenges
5.1.4.1. Lack fo standardized treatment protocols
5.2. Market Segmentation Analysis
5.2.1. Disease type: Need for rapid deployment of treatment strategies for multicentric Castleman’s disease due to the chances of systemic organ failure
5.2.2. Indication: Rising adoption of Castlemann’s disease treatment options for tackling angiomatous lymphoid cases
5.2.3. Treatment: Advancements in chemotherapy treatments leading to expanding adoption of Castleman disease treatment options
5.2.4. Application: Preference for ambulatory surgical centers due to provision of optimum patient care
5.3. Market Disruption Analysis
5.4. Porter’s Five Forces Analysis
5.4.1. Threat of New Entrants
5.4.2. Threat of Substitutes
5.4.3. Bargaining Power of Customers
5.4.4. Bargaining Power of Suppliers
5.4.5. Industry Rivalry
5.5. Value Chain & Critical Path Analysis
5.6. Pricing Analysis
5.7. Technology Analysis
5.8. Patent Analysis
5.9. Trade Analysis
5.10. Regulatory Framework Analysis
6. Castleman Disease Treatment Market, by Disease Type
6.1. Introduction
6.2. Multicentric Castleman’s Disease
6.3. Unicentric Castleman’s Disease
7. Castleman Disease Treatment Market, by Indication
7.1. Introduction
7.2. Angiofollicular Lymph Node Hyperplasia
7.3. Angiomatous Lymphoid
7.4. Castleman Tumor
7.5. Giant Benign Lymphoma
7.6. Giant Lymph Node Hyperplasia
7.7. Hamartoma of the Lyphatics
8. Castleman Disease Treatment Market, by Treatment
8.1. Introduction
8.2. Antiviral Drugs
8.3. Chemotherapy
8.4. Corticosteroids
8.5. Immunotherapy
8.6. Monoclonal Antibodies
8.7. Radiation Therapy
9. Castleman Disease Treatment Market, by Application
9.1. Introduction
9.2. Ambulatory Surgical Centers
9.3. Hospitals
10. Americas Castleman Disease Treatment Market
10.1. Introduction
10.2. Argentina
10.3. Brazil
10.4. Canada
10.5. Mexico
10.6. United States
11. Asia-Pacific Castleman Disease Treatment Market
11.1. Introduction
11.2. Australia
11.3. China
11.4. India
11.5. Indonesia
11.6. Japan
11.7. Malaysia
11.8. Philippines
11.9. Singapore
11.10. South Korea
11.11. Taiwan
11.12. Thailand
11.13. Vietnam
12. Europe, Middle East & Africa Castleman Disease Treatment Market
12.1. Introduction
12.2. Denmark
12.3. Egypt
12.4. Finland
12.5. France
12.6. Germany
12.7. Israel
12.8. Italy
12.9. Netherlands
12.10. Nigeria
12.11. Norway
12.12. Poland
12.13. Qatar
12.14. Russia
12.15. Saudi Arabia
12.16. South Africa
12.17. Spain
12.18. Sweden
12.19. Switzerland
12.20. Turkey
12.21. United Arab Emirates
12.22. United Kingdom
13. Competitive Landscape
13.1. Market Share Analysis, 2023
13.2. FPNV Positioning Matrix, 2023
13.3. Competitive Scenario Analysis
13.3.1. FDA Approves Tocilizumab Biosimilar Tofidence
13.3.2. Chugai Obtains Approval for Additional Indication of Actemra for Cytokine Release Syndrome Induced by Cancer Therapy in Japan
13.3.3. Medable Partners with Every Cure to Accelerate Discovery of Treatments for Rare Diseases
13.4. Strategy Analysis & Recommendation
14. Competitive Portfolio
14.1. Key Company Profiles
14.2. Key Product Portfolio
List of Figures
FIGURE 1. CASTLEMAN DISEASE TREATMENT MARKET RESEARCH PROCESS
FIGURE 2. CASTLEMAN DISEASE TREATMENT MARKET SIZE, 2023 VS 2030
FIGURE 3. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY REGION, 2023 VS 2030 (%)
FIGURE 5. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 6. CASTLEMAN DISEASE TREATMENT MARKET DYNAMICS
FIGURE 7. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2023 VS 2030 (%)
FIGURE 8. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDICATION, 2023 VS 2030 (%)
FIGURE 10. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2023 VS 2030 (%)
FIGURE 12. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
FIGURE 14. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 15. AMERICAS CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 16. AMERICAS CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 17. UNITED STATES CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY STATE, 2023 VS 2030 (%)
FIGURE 18. UNITED STATES CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 19. ASIA-PACIFIC CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 20. ASIA-PACIFIC CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 21. EUROPE, MIDDLE EAST & AFRICA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 22. EUROPE, MIDDLE EAST & AFRICA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 23. CASTLEMAN DISEASE TREATMENT MARKET SHARE, BY KEY PLAYER, 2023
FIGURE 24. CASTLEMAN DISEASE TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023
List of Tables
TABLE 1. CASTLEMAN DISEASE TREATMENT MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
TABLE 3. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, 2018-2023 (USD MILLION)
TABLE 4. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, 2024-2030 (USD MILLION)
TABLE 5. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY REGION, 2018-2023 (USD MILLION)
TABLE 6. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY REGION, 2024-2030 (USD MILLION)
TABLE 7. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
TABLE 8. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
TABLE 9. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY MULTICENTRIC CASTLEMAN’S DISEASE, BY REGION, 2018-2023 (USD MILLION)
TABLE 10. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY MULTICENTRIC CASTLEMAN’S DISEASE, BY REGION, 2024-2030 (USD MILLION)
TABLE 11. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY UNICENTRIC CASTLEMAN’S DISEASE, BY REGION, 2018-2023 (USD MILLION)
TABLE 12. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY UNICENTRIC CASTLEMAN’S DISEASE, BY REGION, 2024-2030 (USD MILLION)
TABLE 13. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
TABLE 14. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
TABLE 15. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY ANGIOFOLLICULAR LYMPH NODE HYPERPLASIA, BY REGION, 2018-2023 (USD MILLION)
TABLE 16. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY ANGIOFOLLICULAR LYMPH NODE HYPERPLASIA, BY REGION, 2024-2030 (USD MILLION)
TABLE 17. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY ANGIOMATOUS LYMPHOID, BY REGION, 2018-2023 (USD MILLION)
TABLE 18. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY ANGIOMATOUS LYMPHOID, BY REGION, 2024-2030 (USD MILLION)
TABLE 19. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY CASTLEMAN TUMOR, BY REGION, 2018-2023 (USD MILLION)
TABLE 20. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY CASTLEMAN TUMOR, BY REGION, 2024-2030 (USD MILLION)
TABLE 21. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY GIANT BENIGN LYMPHOMA, BY REGION, 2018-2023 (USD MILLION)
TABLE 22. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY GIANT BENIGN LYMPHOMA, BY REGION, 2024-2030 (USD MILLION)
TABLE 23. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY GIANT LYMPH NODE HYPERPLASIA, BY REGION, 2018-2023 (USD MILLION)
TABLE 24. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY GIANT LYMPH NODE HYPERPLASIA, BY REGION, 2024-2030 (USD MILLION)
TABLE 25. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY HAMARTOMA OF THE LYPHATICS, BY REGION, 2018-2023 (USD MILLION)
TABLE 26. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY HAMARTOMA OF THE LYPHATICS, BY REGION, 2024-2030 (USD MILLION)
TABLE 27. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
TABLE 28. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
TABLE 29. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY ANTIVIRAL DRUGS, BY REGION, 2018-2023 (USD MILLION)
TABLE 30. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY ANTIVIRAL DRUGS, BY REGION, 2024-2030 (USD MILLION)
TABLE 31. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2018-2023 (USD MILLION)
TABLE 32. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2024-2030 (USD MILLION)
TABLE 33. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2018-2023 (USD MILLION)
TABLE 34. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2024-2030 (USD MILLION)
TABLE 35. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2018-2023 (USD MILLION)
TABLE 36. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2024-2030 (USD MILLION)
TABLE 37. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2023 (USD MILLION)
TABLE 38. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2024-2030 (USD MILLION)
TABLE 39. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY RADIATION THERAPY, BY REGION, 2018-2023 (USD MILLION)
TABLE 40. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY RADIATION THERAPY, BY REGION, 2024-2030 (USD MILLION)
TABLE 41. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 42. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 43. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2023 (USD MILLION)
TABLE 44. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2024-2030 (USD MILLION)
TABLE 45. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2023 (USD MILLION)
TABLE 46. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2024-2030 (USD MILLION)
TABLE 47. AMERICAS CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
TABLE 48. AMERICAS CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
TABLE 49. AMERICAS CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
TABLE 50. AMERICAS CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
TABLE 51. AMERICAS CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
TABLE 52. AMERICAS CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
TABLE 53. AMERICAS CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 54. AMERICAS CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 55. AMERICAS CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
TABLE 56. AMERICAS CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
TABLE 57. ARGENTINA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
TABLE 58. ARGENTINA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
TABLE 59. ARGENTINA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
TABLE 60. ARGENTINA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
TABLE 61. ARGENTINA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
TABLE 62. ARGENTINA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
TABLE 63. ARGENTINA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 64. ARGENTINA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 65. BRAZIL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
TABLE 66. BRAZIL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
TABLE 67. BRAZIL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
TABLE 68. BRAZIL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
TABLE 69. BRAZIL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
TABLE 70. BRAZIL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
TABLE 71. BRAZIL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 72. BRAZIL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 73. CANADA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
TABLE 74. CANADA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
TABLE 75. CANADA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
TABLE 76. CANADA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
TABLE 77. CANADA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
TABLE 78. CANADA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
TABLE 79. CANADA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 80. CANADA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 81. MEXICO CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
TABLE 82. MEXICO CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
TABLE 83. MEXICO CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
TABLE 84. MEXICO CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
TABLE 85. MEXICO CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
TABLE 86. MEXICO CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
TABLE 87. MEXICO CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 88. MEXICO CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 89. UNITED STATES CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
TABLE 90. UNITED STATES CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
TABLE 91. UNITED STATES CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
TABLE 92. UNITED STATES CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
TABLE 93. UNITED STATES CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
TABLE 94. UNITED STATES CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
TABLE 95. UNITED STATES CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 96. UNITED STATES CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 97. UNITED STATES CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY STATE, 2018-2023 (USD MILLION)
TABLE 98. UNITED STATES CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY STATE, 2024-2030 (USD MILLION)
TABLE 99. ASIA-PACIFIC CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
TABLE 100. ASIA-PACIFIC CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
TABLE 101. ASIA-PACIFIC CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
TABLE 102. ASIA-PACIFIC CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
TABLE 103. ASIA-PACIFIC CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
TABLE 104. ASIA-PACIFIC CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
TABLE 105. ASIA-PACIFIC CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 106. ASIA-PACIFIC CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 107. ASIA-PACIFIC CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
TABLE 108. ASIA-PACIFIC CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
TABLE 109. AUSTRALIA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
TABLE 110. AUSTRALIA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
TABLE 111. AUSTRALIA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
TABLE 112. AUSTRALIA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
TABLE 113. AUSTRALIA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
TABLE 114. AUSTRALIA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
TABLE 115. AUSTRALIA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 116. AUSTRALIA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 117. CHINA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
TABLE 118. CHINA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
TABLE 119. CHINA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
TABLE 120. CHINA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
TABLE 121. CHINA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
TABLE 122. CHINA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
TABLE 123. CHINA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 124. CHINA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 125. INDIA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
TABLE 126. INDIA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
TABLE 127. INDIA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
TABLE 128. INDIA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
TABLE 129. INDIA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
TABLE 130. INDIA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
TABLE 131. INDIA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 132. INDIA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 133. INDONESIA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
TABLE 134. INDONESIA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
TABLE 135. INDONESIA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
TABLE 136. INDONESIA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
TABLE 137. INDONESIA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
TABLE 138. INDONESIA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
TABLE 139. INDONESIA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 140. INDONESIA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 141. JAPAN CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
TABLE 142. JAPAN CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
TABLE 143. JAPAN CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
TABLE 144. JAPAN CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
TABLE 145. JAPAN CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
TABLE 146. JAPAN CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
TABLE 147. JAPAN CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 148. JAPAN CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 149. MALAYSIA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
TABLE 150. MALAYSIA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
TABLE 151. MALAYSIA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
TABLE 152. MALAYSIA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
TABLE 153. MALAYSIA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
TABLE 154. MALAYSIA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
TABLE 155. MALAYSIA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 156. MALAYSIA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 157. PHILIPPINES CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
TABLE 158. PHILIPPINES CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
TABLE 159. PHILIPPINES CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
TABLE 160. PHILIPPINES CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
TABLE 161. PHILIPPINES CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
TABLE 162. PHILIPPINES CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
TABLE 163. PHILIPPINES CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 164. PHILIPPINES CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 165. SINGAPORE CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
TABLE 166. SINGAPORE CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
TABLE 167. SINGAPORE CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
TABLE 168. SINGAPORE CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
TABLE 169. SINGAPORE CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
TABLE 170. SINGAPORE CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
TABLE 171. SINGAPORE CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 172. SINGAPORE CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 173. SOUTH KOREA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
TABLE 174. SOUTH KOREA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
TABLE 175. SOUTH KOREA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
TABLE 176. SOUTH KOREA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
TABLE 177. SOUTH KOREA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
TABLE 178. SOUTH KOREA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
TABLE 179. SOUTH KOREA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 180. SOUTH KOREA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 181. TAIWAN CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
TABLE 182. TAIWAN CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
TABLE 183. TAIWAN CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
TABLE 184. TAIWAN CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
TABLE 185. TAIWAN CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
TABLE 186. TAIWAN CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
TABLE 187. TAIWAN CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 188. TAIWAN CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 189. THAILAND CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
TABLE 190. THAILAND CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
TABLE 191. THAILAND CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
TABLE 192. THAILAND CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
TABLE 193. THAILAND CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
TABLE 194. THAILAND CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
TABLE 195. THAILAND CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 196. THAILAND CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 197. VIETNAM CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
TABLE 198. VIETNAM CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
TABLE 199. VIETNAM CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
TABLE 200. VIETNAM CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
TABLE 201. VIETNAM CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
TABLE 202. VIETNAM CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
TABLE 203. VIETNAM CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 204. VIETNAM CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 205. EUROPE, MIDDLE EAST & AFRICA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
TABLE 206. EUROPE, MIDDLE EAST & AFRICA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
TABLE 207. EUROPE, MIDDLE EAST & AFRICA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
TABLE 208. EUROPE, MIDDLE EAST & AFRICA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
TABLE 209. EUROPE, MIDDLE EAST & AFRICA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
TABLE 210. EUROPE, MIDDLE EAST & AFRICA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
TABLE 211. EUROPE, MIDDLE EAST & AFRICA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 212. EUROPE, MIDDLE EAST & AFRICA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 213. EUROPE, MIDDLE EAST & AFRICA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
TABLE 214. EUROPE, MIDDLE EAST & AFRICA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
TABLE 215. DENMARK CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
TABLE 216. DENMARK CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
TABLE 217. DENMARK CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
TABLE 218. DENMARK CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
TABLE 219. DENMARK CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
TABLE 220. DENMARK CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
TABLE 221. DENMARK CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 222. DENMARK CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 223. EGYPT CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
TABLE 224. EGYPT CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
TABLE 225. EGYPT CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
TABLE 226. EGYPT CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
TABLE 227. EGYPT CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
TABLE 228. EGYPT CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
TABLE 229. EGYPT CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 230. EGYPT CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 231. FINLAND CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
TABLE 232. FINLAND CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
TABLE 233. FINLAND CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
TABLE 234. FINLAND CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
TABLE 235. FINLAND CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
TABLE 236. FINLAND CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
TABLE 237. FINLAND CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 238. FINLAND CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 239. FRANCE CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
TABLE 240. FRANCE CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
TABLE 241. FRANCE CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
TABLE 242. FRANCE CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
TABLE 243. FRANCE CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
TABLE 244. FRANCE CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
TABLE 245. FRANCE CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 246. FRANCE CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 247. GERMANY CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
TABLE 248. GERMANY CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
TABLE 249. GERMANY CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
TABLE 250. GERMANY CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
TABLE 251. GERMANY CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
TABLE 252. GERMANY CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
TABLE 253. GERMANY CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 254. GERMANY CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 255. ISRAEL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
TABLE 256. ISRAEL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
TABLE 257. ISRAEL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
TABLE 258. ISRAEL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
TABLE 259. ISRAEL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
TABLE 260. ISRAEL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
TABLE 261. ISRAEL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 262. ISRAEL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 263. ITALY CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
TABLE 264. ITALY CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
TABLE 265. ITALY CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
TABLE 266. ITALY CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
TABLE 267. ITALY CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
TABLE 268. ITALY CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
TABLE 269. ITALY CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 270. ITALY CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 271. NETHERLANDS CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
TABLE 272. NETHERLANDS CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
TABLE 273. NETHERLANDS CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
TABLE 274. NETHERLANDS CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
TABLE 275. NETHERLANDS CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
TABLE 276. NETHERLANDS CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
TABLE 277. NETHERLANDS CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 278. NETHERLANDS CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 279. NIGERIA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
TABLE 280. NIGERIA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
TABLE 281. NIGERIA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
TABLE 282. NIGERIA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
TABLE 283. NIGERIA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
TABLE 284. NIGERIA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
TABLE 285. NIGERIA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 286. NIGERIA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 287. NORWAY CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
TABLE 288. NORWAY CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
TABLE 289. NORWAY CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
TABLE 290. NORWAY CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
TABLE 291. NORWAY CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
TABLE 292. NORWAY CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
TABLE 293. NORWAY CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 294. NORWAY CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 295. POLAND CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
TABLE 296. POLAND CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
TABLE 297. POLAND CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
TABLE 298. POLAND CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
TABLE 299. POLAND CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
TABLE 300. POLAND CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
TABLE 301. POLAND CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 302. POLAND CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 303. QATAR CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
TABLE 304. QATAR CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
TABLE 305. QATAR CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
TABLE 306. QATAR CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
TABLE 307. QATAR CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
TABLE 308. QATAR CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
TABLE 309. QATAR CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 310. QATAR CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 311. RUSSIA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
TABLE 312. RUSSIA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
TABLE 313. RUSSIA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
TABLE 314. RUSSIA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
TABLE 315. RUSSIA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
TABLE 316. RUSSIA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
TABLE 317. RUSSIA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 318. RUSSIA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 319. SAUDI ARABIA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
TABLE 320. SAUDI ARABIA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
TABLE 321. SAUDI ARABIA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
TABLE 322. SAUDI ARABIA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDI

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • AbbVie Inc.
  • Agilent Technologies, Inc.
  • Amgen Inc.
  • Artiva Biotherapeutics, Inc.
  • Bayer AG
  • Bio-Rad Laboratories, Inc.
  • Biogen Inc.
  • Boehringer Ingelheim GmbH
  • Bristol-Myers Squibb Company
  • Cadila Pharmaceuticals Limited
  • Celltrion Healthcare Co.,Ltd.
  • F. Hoffmann-La Roche AG
  • Gilead Sciences, Inc.
  • GlaxoSmithKline PLC
  • Glenmark Pharmaceuticals S.A.
  • Johnson & Johnson Services, Inc.
  • LGM Pharma
  • Merck & Co., Inc.
  • Novartis AG
  • Octapharma AG
  • Pfizer, Inc.
  • Recordati Group Company
  • Recordati S.p.A.
  • Sanofi S.A.
  • Sartorius AG
  • Sun Pharmaceutical Industries Ltd.
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceutical Industries Ltd.
  • Thermo Fisher Scientific Inc.
  • Viatris Inc.

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages191
PublishedJune 2024
Forecast Period2024 - 2030
Estimated Market Value ( USD ) in 2024 $ 334.15 Million
Forecasted Market Value ( USD ) by 2030 $ 719.87 Million
Compound Annual Growth Rate13.6%
Regions CoveredGlobal

Related Topics

Related Reports

Castleman Disease Treatment Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028F - Product Image

Castleman Disease Treatment Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028F

  • Report
  • 178 Pages
  • Global
From
idiopathic Multicentric Castleman's disease (iMCD) - Pipeline Insight, 2024 - Product Image

idiopathic Multicentric Castleman's disease (iMCD) - Pipeline Insight, 2024

  • Drug Pipelines
  • 60 Pages
  • Global
From
Castleman Disease Treatment Global Market Insights 2024, Analysis and Forecast to 2029, by Manufacturers, Regions, Technology, Application - Product Image

Castleman Disease Treatment Global Market Insights 2024, Analysis and Forecast to 2029, by Manufacturers, Regions, Technology, Application

  • Report
  • 93 Pages
  • Global
From
Castleman Disease - Pipeline Insight, 2024 - Product Image

Castleman Disease - Pipeline Insight, 2024

  • Clinical Trials
  • 40 Pages
  • Global
From
Global Cutaneous T-Cell-Lymphoma Market (CTCL) by Indication (Mycosis Fungoides, Sézary Syndrome), Treatment (Biological Therapies, Phototherapy, Radiation Therapy), Product, End-User - Forecast 2024-2030 - Product Image

Global Cutaneous T-Cell-Lymphoma Market (CTCL) by Indication (Mycosis Fungoides, Sézary Syndrome), Treatment (Biological Therapies, Phototherapy, Radiation Therapy), Product, End-User - Forecast 2024-2030

  • Report
  • 199 Pages
  • Global
From

About the Castleman Disease Drugs Market

Castleman Disease (CD) is a rare lymphoproliferative disorder that affects the lymph nodes and other organs. It is classified as a subtype of lymphoma, and is characterized by an overgrowth of lymphoid cells. Treatment for CD typically involves chemotherapy, radiation therapy, and/or immunosuppressive drugs. The Castleman Disease Drugs market is a subset of the larger Lymphoma Drugs market. It is composed of drugs used to treat CD, such as monoclonal antibodies, interferons, and corticosteroids. These drugs are used to reduce the size of lymph nodes, reduce inflammation, and suppress the immune system. Some companies in the Castleman Disease Drugs market include AbbVie, Bristol-Myers Squibb, Celgene, Gilead Sciences, and Novartis. Show Less Read more

Copyright © 2002-2024 Research and Markets. All Rights Reserved.